Innovations in liposomal formulations for antimicrobial therapy

Bibliography

• LOEFFLER J, STEVENS DA: Antifungal drug resistance. Clin. Infect. Dis. (2003) 36\(Supp1.1):S31–S41.
   Google Scholar
• FLEMING RV, WALSH TJ, ANAISSIE EJ: Emerging and less common fungal pathogens. Infect. Dis. Clin. North Am. (2002) 16(4):915–933.
   PubMedGoogle Scholar
• CUNHA BA: Pneumonias in the compromised host. Infect. Dis. Clin. North Am. (2001) 15(2):591–612.
   PubMedGoogle Scholar
• BODEY GP, ROLSTON KV: Management of fever in neutropenic patients. I Infect. Chemother. (2001) 7(1):1–9.
   PubMedGoogle Scholar
• CASADEVALL A, PIROFSKI L: Host-pathogen interactions: the attributes of virulence.' Infect. Dis. (2001) 184(3)337–344.
   Google Scholar
• WEED HG: Antimicrobial prophylaxis in the surgical patient. Med. Clin. North Am. (2003) 87(1):59–75.
   PubMed Web of Science ®Google Scholar
• GHANNOUM MA, RICE LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbial. Rev (1999) 12(4):501–517.
   PubMed Web of Science ®Google Scholar
• BUSH K: Antimicrobial agents. Curr. Opin. Chem. Biol. (1997) 1(2):169–175.
   PubMed Web of Science ®Google Scholar
• CHOPRA I: Research and development of antibacterial agents. Curr. Opin. Microbial. (1998) 1(5):495–501.
   PubMedGoogle Scholar
• DEMAIN AL, ELANDER RP: The 13-lactam antibiotics: past, present, and future. Antonie Van Leeuwenhoek (1999) 75(1-2):5–19.
   PubMedGoogle Scholar
• SMITH GD, MARMOT MG: Trends in mortality in Britain: 1920–1986. Ann. Num. Metab. (1991) 35\(Supp1.1):53–63.
   Google Scholar
• GYSSENS IC: Quality measures of antimicrobial drug use. Int. Antimicrob. Agents (2001) 17(1):9–19.
   PubMedGoogle Scholar
• GARCIA-CARBONERO R, PAZ-ARES L: Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr. Opin. Hematol (2002) 9(3):215–221.
   PubMedGoogle Scholar
• DONOWITZ GR, MAKI DG, CRNICH CJ, PAPPAS PG, ROLSTON KV: Infections in the neutropenic patient - new views of an old problem. Hematology (Am. Soc. Hematol Educ. Program) (2001):113–139.
   PubMedGoogle Scholar
• ••Thorough review of the problems encounteredin the neutropenic patient population.
   Google Scholar
• ZINNER SH: New pathogens in neutropenic patients with cancer: an update for the new millennium. Int. I Antimicrob. Agents (2000) 16(2):97–101.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J: Empirical treatment of sepsis in neutropenic patients. Int. J. Antimicrob. Agents (2000) 16(2):131–133.
   PubMedGoogle Scholar
• WADE JC: Current issues in the treatment of resistant bloodstream infections. Oncology aluntingt) (2000) 14(8Supp1.6):35–39.
   Google Scholar
• •Review that pays particular attention to the issues of drug resistance and shifts in prevalence of microorganisms.
   Google Scholar
• DE MARIE S: New developments in the diagnosis and management of invasive fungal infections. Haematologica (2000) 85(1):88–93.
   PubMedGoogle Scholar
• •Update on the increase in fungal infections In immunocompromised patients and ways to detect and combat them.
   Google Scholar
• SCHREIER H: Preface. In: Drug targeting technology: physical, chemical and biological methods. Shreier H (Ed.), Marcel Dekker, New York, USA (2001):iii-ix.
   Google Scholar
• MOLEMA G: Drug targeting: basic concepts, and novel advances. In: Drug Targeting: Organ-Specific Strategies, Mannhold R, Kubinyi H, Timmerman H (Eds), John Wiley & Sons, Germany (2001):1–20.
   Google Scholar
• ••Complete overview of novel concepts indrug delivery research.
   Google Scholar
• DUNCAN R: Drug targeting: where are we now and where are we going?" Drug Target. (1997) 5(1):1–4.
   Google Scholar
• MILLER G: Drug targeting. Breaking down barriers. Science (2002) 297(5584):1116–1118.
   Google Scholar
• BRANDL M: Liposomes as drug carriers: a technological approach. Biotechnol Ann. Rev (2001) 7:59–85.
   PubMedGoogle Scholar
• ALLEN TM: Liposomes. Opportunities in drug delivery. Drugs (1997) 54\(Suppl. 4):8–14.
   Google Scholar
• VENUGOPALAN P, JAIN S, SANKAR S, SINGH P, RAWAT A, WAS SP: pH-sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects. Pharmazie (2002) 57(10):659–671.
   PubMedGoogle Scholar
• YATVIN MB, WEINSTEIN JN, DENNIS WH, BLUMENTHAL R: Design of liposomes for enhanced local release of drugs by hyperthermia. Science (1978) 202(4374):1290–1293.
   PubMed Web of Science ®Google Scholar
• YATVIN MB, KREUTZ W, HORWITZ BA, SHINITZKY M: pH-sensitive liposomes: possible clinical implications. Science (1980) 210(4475):1253–1255.
   PubMed Web of Science ®Google Scholar
• BANERJEE R: Liposomes: applications in medicine. J. Biomater. Appl. (2001) 16(1):3–21.
   PubMedGoogle Scholar
• JONES MN: The surface properties of phospholipid liposome systems and their characterisation. Adv. Colloid Interface Li. (1995) 54:93–128.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G: Engineering liposomes for drug delivery: progress and problems. Trends Biotech. (1995) 13(12):527–537.
   PubMed Web of Science ®Google Scholar
• PAPAHADJOPOULOS D, GABIZON A: Liposomes designed to avoid the reticuloendothelial system. Frog. Clin. Biol. Res. (1990) 343:85–93.
   PubMedGoogle Scholar
• SZOKA F JR, PAPAHADJOPOULOS D: Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev Biophys Bioeng. (1980) 9:467–508.
   PubMedGoogle Scholar
• WINTERHALTER M, LASIC DD: Liposome stability and formation: experimental parameters and theories on the size distribution. Chem. Phys. Lipids (1993) 64(1-3):35–43.
   PubMed Web of Science ®Google Scholar
• WASAN KM, LOPEZ-BERESTEIN G: Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin. Infect. Dis. (1996) 23(5):1126–1138.
   PubMed Web of Science ®Google Scholar
• ULRICH AS: Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep. (2002) 22(2):129–150.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G: The carrier potential of liposomes in biology and medicine. N Engl. J. Med. (1976) 295(14):765–770.
   PubMed Web of Science ®Google Scholar
• PRICE CI, HORTON JW, BAXTER CR: Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery (1994) 115(4):480–487.
   PubMed Web of Science ®Google Scholar
• GRUET P, MAINCENT P, BERTHELOT X, KALTSATOS V: Bovine mastitis and intramammary drug delivery: review and perspectives. Adv. Drug Deily. Rev (2001) 50(3):245–259.
   PubMed Web of Science ®Google Scholar
• DESGRANDCHAMPS F: Biomaterials in functional reconstruction. Curl: Opin. Urol (2000) 10(3):201–206.
   PubMedGoogle Scholar
• BURROWS LL, KHOURY AE: Issues surrounding the prevention and management of device-related infections. World 1 Urol. (1999) 17(6):402–409.
   Google Scholar
• HONEYBOURNE D: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr. Opin. Pulm. Med. (1997) 3(2):170–174.
   PubMedGoogle Scholar
• REIMER K, FLEISCHER W, BROGMANN B et al: Povidone-iodine liposomes - an overview. Dermatology (1997) 195\(Supp1.2):93–99.
   Google Scholar
• MOGHIMI SM, PATEL HM: Current progress and future prospects of liposomes in dermal drug delivery. I. Microencapsul (1993) 10(2):155–162.
   PubMed Web of Science ®Google Scholar
• METRIKIN DC, ANAND R: Intravitreal drug administration with depot devices. Curl: Opin. Ophrhalmol. (1994) 5(3):21–29.
   PubMedGoogle Scholar
• MOURITSEN OG, JORGENSEN K: A new look at lipid-membrane structure in relation to drug research. Pharm. Res. (1998) 15(10):1507–1519.
   PubMed Web of Science ®Google Scholar
• FINELLI A, BURROWS LL, DICOSMO FA et al: Colonization-resistant antimicrobial-coated peritoneal dialysis catheters: evaluation in a newly developed rat model of persistent Pseudomonas aeruginosa peritonitis. Petit. Dial. Int. (2002) 22(1):27–31.
   PubMedGoogle Scholar
• PUGACH JL, DITIZIO V, MITTELMAN MW et al.: Antibiotic hydrogel coated Foley catheters for prevention of urinary tract infection in a rabbit model. I. Ural. (1999) 162(3Pt1):883–887.
   Google Scholar
• JORGENSEN K, DAVIDSEN J, MOURITSEN OG: Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery. FEBS Lett. (2002) 531(1):23–27.
   PubMedGoogle Scholar
• BEAULAC C, CLEMENT-MAJORS, HAWARI J, LAGACE J: In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. .1 Microencapsul. (1997) 14(3):335–348.
   Google Scholar
• LAGACE J, DUBREUIL M, MONTPLAISIR S: Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa. Microencapsul (1991) 8(1):53–61.
   PubMed Web of Science ®Google Scholar
• OMRI A, SUNTRES ZE, SHEK PN: Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol (2002) 64(9):1407–1413.
   PubMed Web of Science ®Google Scholar
• RUIJGROK EJ, VULTO AG, VAN ETTEN EW: Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. .1 Antanicrob. Chernother (2001) 48(1):89–95.
   Google Scholar
• BEAULAC C, SACHETELLI S, LAGACE J: Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. I. Drug Target. (1999) 7(1):33–41.
   PubMed Web of Science ®Google Scholar
• OMRI A, BEAULAC C, BOUHAJIB M, MONTPLAISIR S, SHARKAWI M, LAGACE J: Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother (1994) 38(5):1090–1095.
   PubMed Web of Science ®Google Scholar
• CONLEY J, YANG H, WILSON T et al: Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother (1997) 41(6):1288–1292.
   PubMed Web of Science ®Google Scholar
• DI ROCCO PH, NACUCCHIO MC, SORDELLI DO, MANCUSO F, HOOKE AM: The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection. Infection (1992) 20(6):360–364.
   PubMedGoogle Scholar
• DESJARDINS A, CHEN T, KHALIL H, SAYASITH K, LAGACE J: Differential behaviour of fluid liposomes toward mammalian epithelial cells and bacteria: restriction of fusion to bacteria. J. Drug Target. (2002) 10(1):47–54.
   PubMed Web of Science ®Google Scholar
• SACHETELLI S, KHALIL H, CHEN T, BEAULAC C, SENECHAL S, LAGACE J: Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta. (2000) 1463(2):254–266.
   PubMed Web of Science ®Google Scholar
• BEAULAC C, SACHETELLI S, LAGACE J: hi vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. .I. Antimicrob. Chemother. (1998) 41(1):35–41.
   PubMedGoogle Scholar
• PRICE CI, HORTON JW, BAXTER CR: Enhanced effectiveness of intraperitoneal antibiotics administered via liposomal carrier. Arch. Surg. (1989) 124(12):1411–1414.
   PubMedGoogle Scholar
• PRICE CI, HORTON JW, BAXTER CR: Topical liposomal delivery of antibiotics in soft tissue infection. J. Surg. Res. (1990) 49(2):174–178.
   PubMedGoogle Scholar
• PRICE CI, HORTON JW, BAXTER CR: Liposome delivery of aminoglycosides in burn wounds. Surg. Cyriecol Obstet. (1992) 174(5):414–418.
   PubMedGoogle Scholar
• FRUCHT-PERRY J, ASSIL KK, ZIEGLER E et al.: Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratin's. Cornea (1992) 11(5):393–397.
   PubMedGoogle Scholar
• DAVIS SD, SARFF LD, HYNDIUK RA: Topical tobramycin therapy of experimental Pseudomonas keratitic an evaluation of some factors that potentially enhance efficacy. Arch. Ophthalmol (1978) 96 (1):123–125.
   PubMedGoogle Scholar
• TRAFNY EA, ANTOS-BIELSKA M, GRZYBOWSKI J: Antibacterial activity of liposome-encapsulated antibiotics against Pseudomonas aeruginosa attached to the matrix of human dermis. 1 Microencapsul (1999) 16(4):419–429.
   Google Scholar
• HUH J, CHEN JC, FURMAN GM et al: Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin. Surg. Res. (1998) 74(1):54–58.
   PubMedGoogle Scholar
• REIMER K, VOGT PM, BROEGMANN B et al: An innovative topical drug formulation for wound healing and infection treatment: in vitro and in vivo investigations of a povidone-iodine liposome hydrogel. Dermatology (2000) 201(3):235–241.
   PubMed Web of Science ®Google Scholar
• WUTZLER P, SAUERBREI A, KLOCKING R et al.: Virucidal and chlamydicidal activities of eye drops with povidone-iodine liposome complex. Ophthalmic Res. (2000) 32(2-3):118–125.
   PubMedGoogle Scholar
• REIMER K, FLEISCHER W, BROGMANN B et al.: Povidone-iodine liposomes-an overview. Dermatology (1997) 195\(Supp1.2):93–99.
   Google Scholar
• ROBINSON AM, CREETH JE, JONES MN: The use of immunoliposomes for specific delivery of antimicrobial agents to oral bacteria immobilized on polystyrene. Biomater. Li. Polym. Ed (2000) 11(12):1381–1393.
   PubMed Web of Science ®Google Scholar
• CHO YH, LEE SJ, LEE JY et al: Antibacterial effect of intraprostatic zinc injection in a rat model of chronic bacterial prostatitis. Int. Antimicrob. Agents (2002) 19(6):576–582.
   PubMedGoogle Scholar
• LANGE CE HANCOCK RE, SAMUEL J, FINLAY WH: In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J. Pharm. Sci. (2001) 90(10):1647–1657.
   PubMedGoogle Scholar
• PAVELIC Z, SKALKO-BASNET N, JALSENJAK I: Liposomes containing drugs for treatment of vaginal infections. Eur. Pharm. Sci. (1999) 8(4):345–351.
   PubMedGoogle Scholar
• BAKKER-WOUDENBERG IA, STORM G, WOODLE MC: Liposomes in the treatment of infections. J. Drug Target. (1994) 2(5):363–371.
   PubMed Web of Science ®Google Scholar
• AHSAN F, RIVAS IP, KHAN MA, TORRES SUAREZ Al: Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J. Control. Release (2002) 79(1-3):29–40.
   PubMed Web of Science ®Google Scholar
• •Most recent evaluation of drug delivery systems targeting macrophages.
   Google Scholar
• MOGHIMI SM, HUNTER AC: Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res. (2001) 18(1):1–8.
   PubMed Web of Science ®Google Scholar
• VAN ROOIJEN N, WIJBURG OL, VAN DEN DOBBELSTEEN GP, SANDERS A: Macrophages in host defense mechanisms. Curr. Top. Microbial. Immunol (1996) 210:159–165.
   PubMedGoogle Scholar
• SCHROIT AJ, MADSEN J, NAYAR R: Liposome-cell interactions: in vitro discrimination of uptake mechanism and in vivo targeting strategies to mononuclear phagocytes. Chem. Phys. Lipids (1986) 40(2–4)373–393.
   Google Scholar
• BRADLEY AJ, DEVINE DV: The complement system in liposome clearance: can complement deposition be inhibited? Adv. Drug Deify. Rev (1998) 32(1-2):19–29.
   PubMedGoogle Scholar
• SZEBENI J: The interaction of liposomes with the complement system. Crit. Rev Ther. Drug Carrier Syst. (1998) 15(1):57–88.
   PubMed Web of Science ®Google Scholar
• COUVREURP, FATTAL E, ANDREMONT A: Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm. Res (1991) 8(9):1079–1086.
   PubMedGoogle Scholar
• PINTO-ALPHANDARY H, ANDREMONT A, COUVREUR P: Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. Antimicrob. Agents (2000) 13(3):155–168.
   PubMed Web of Science ®Google Scholar
• •A comprehensive overview of drug delivery systems in antimicrobial treatment also focusing on polymer-based nanoparticles.
   Google Scholar
• MELISSEN PM, VAN VIANEN W, RIJSBERGEN Y, BAKKER-WOUDENBERG IA: Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection. Infect. Immun. (1992) 60(1):95–101.
   PubMedGoogle Scholar
• HOCKERTZ S, FRANKE G, PAULINI I, LOHMANN-MATTHES ML: Immunotherapy of murine visceral leishmaniasis with murine recombinant IFN-y and MTP-PE encapsulated in liposomes. J. Interferon Res. (1991) 11(3):177–185.
   PubMedGoogle Scholar
• TEN HAGEN TL, VAN VIANEN W BAKKER-WOUDENBERG IA: Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneurnoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and IFN-y aloneor combined. J. Infect. Da (1995) 171(2):385–392.
   PubMedGoogle Scholar
• SUCH J, FRANCES R, PEREZ-MATEO M: Nitric oxide in patients with cirrhosis and bacterial infections. Metab. Broth Dis. (2002) 17(4):303–309.
   PubMedGoogle Scholar
• CLEMONS KV, STEVENS DA: Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Sernin. Respir. Infect. (2001) 16(1):60–66.
   PubMedGoogle Scholar
• COLEMAN JW: Nitric oxide in immunity and inflammation. Int. Inonunopharmacol. (2001) 1(8):1397–1406.
   PubMed Web of Science ®Google Scholar
• RIESBECK K: Immunomodulating activity of quinolones: review. Chemother (2002) 14(1):3–12.
   Google Scholar
• PURSWANI MU, ECKERT SJ, ARORA HK, NOEL GJ: Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. j Antlinicrob. Chemother (2002) 50(1):51–58.
   PubMedGoogle Scholar
• JAYAKUMAR K, HONNEGOWDA, KRISHNAPPA G, SASTRY KN, NARAYANA K: Effect of ciprofloxacin on specific immune response in rabbits. Indian J. Exp. Biol. (2002) 40(1):111–114.
   PubMedGoogle Scholar
• WONG JP, SCHNELL G, SIMPSON M, SARAVOLAC E: Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylcoccus aureus by murine macrophages. Aral Cells Blood Substit. Immobil. Biotechnol. (2000) 28(5):415–428.
   PubMed Web of Science ®Google Scholar
• HAINES DS, STRAUSS KI, GILLESPIE DH: Cellular response to double-stranded RNA. J. Cell Biochern (1991) 46(1):9–20.
   PubMedGoogle Scholar
• AGRAWAL S, KANDIMALLA ER: Antisense and/or immunostimulatory oligonucleotide therapeutics. Curl: Cancer Drug Targets (2001) 1(3):197–209.
   PubMedGoogle Scholar
• WONG JP, YANG H, NAGATA L et al: Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine (1999) 17(13-14):1788–1795.
   PubMedGoogle Scholar
• SARAVOLAC EG, SABUDA D, CRIST C et al.: Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine (2001) 19(17-19):2227–2232.
   PubMedGoogle Scholar
• SULLENGER BA, GILBOA E: Emerging clinical applications of RNA. Nature (2002) 418(6894):252–258.
   PubMed Web of Science ®Google Scholar
• GEWIRTZ AM: Oligonucleotide therapeutics: clothing the emperor. Curr. Opin. Mol. Ther. (1999) 1(3):297–306.
   PubMedGoogle Scholar
• DUPONT B: Overview of the lipid formulations of amphotericin B. I Antlinicrob. Chemother (2002) 49\(Supp1.1):31–36
   Google Scholar
• ARIKAN S, REX JH: Lipid-based antifungal agents: current status. Curr. Pharm. Des. (2001) 7(5):393–415.
   PubMedGoogle Scholar
• •Thorough overview of the similarities and differences of the lipid formulations of antifungal agents.
   Google Scholar
• ROBINSON RF, NAHATA MC: A comparative review of conventional and lipid formulations of amphotericin Pharm. Ther. (1999) 24(4):249–257.
   Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Cl/n. Infect. Da (1998) 27(3):603–618.
   PubMed Web of Science ®Google Scholar
• ADLER-MOORE J, PROFFITT RT: AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antirnicrob. Chemother (2002)116.49\(Supp1.1):21–30.
   Google Scholar
• GROLL AH, MICKIENE D, WERNER K et al.: Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob. Agents Chemother (2000) 44(4):950–957.117.
   Google Scholar
• ARMSON A, KAMAU SW, GRIMM F et al.: A comparison of the effects of a benzimidazole and the dinitroanilines against Leishrnania infanturn Acta Trop. (1999) 73(3):303–311.
   Google Scholar
• CHAN MM, FONG D: Inhibition of118.leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science (1990) 249(4971):924–926.
   Google Scholar
• CHAN MM, GROGL M, CHEN CC, BIENEN EJ, FONG D: Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans. Proc. Nati Acad. SciUSA (1993) 90(12):5657–5661.
   PubMedGoogle Scholar
• ALLEN C, DOS SANTOS N, GALLAGHER R eta].: Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). I3iosci. Rep. (2002) 22(2):225–250.
   Google Scholar
• BAKKER-WOUDENBERG IA: Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int. J. Antlinicrob. Agents (2002) 19(4):299–311.
   PubMed Web of Science ®Google Scholar
• MOGHIMI SM, HUNTER AC, MURRAY JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev (2001) 53(2):283–318.
   PubMed Web of Science ®Google Scholar
• MAURER N, FENSKE DB, CULLIS PR: Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther. (2001) 1(6):923–947.
   PubMed Web of Science ®Google Scholar
• SEMPLE SC, CHONN A, CULLIS PR: Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry (Mo s (1996) 35(8):2521–2525.
   PubMed Web of Science ®Google Scholar
• LIU D, LIU F, SONG YK: Monosialoganglioside GM1 shortens the blood circulation time of liposomes in rats. Pharm. Res. (1995) 12(4):508–512.
   PubMed Web of Science ®Google Scholar
• TORCHILIN VP: Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul. (1998) 15(1):1–19.
   PubMed Web of Science ®Google Scholar
• WOODLE MC, LASIC DD: Sterically stabilized liposomes. Biochlin. Biophys. Acta (1992) 1113(2):171–199.
   PubMed Web of Science ®Google Scholar
• •Sound evaluation of the most important data leading to the concept of steric stabilisation of drug delivery systems.
   Google Scholar
• BOERMAN OC, OYEN WJ, VAN BLOOIS L et al.: Optimization of [99m-technetium]-labeled PEG liposomes to image focal infection: effects of particle size and circulation time. J. Nucl. Med. (1997) 38(3):489–493.
   Google Scholar
• AWASTHI V, GOINS B, KLIPPER R, LOREDO R, KORVICK D, PHILLIPS WT: Imaging experimental osteomyelitis using radiolabeled liposomes. Nucl. Med. (1998) 39(6):1089–1094.
   Google Scholar
• BECKER MJ, DAMS ET, DE MARIE S et al.: Scintigraphic imaging using [99mTc] -labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. Nucl. Med. Biol. (2002) 29(2):177–184.
   Google Scholar
• STEARNE LE, SCHIFFELERS RM, SMOUTER E, BAKKER-WOUDENBERG IA, GYSSENS IC: Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses. Biochlin. Biophys. Acta (2002) 1561(1):91–97.
   PubMedGoogle Scholar
• SCHIFFELERS RM, STORM G, BAKKER-WOUDENBERG IA: Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneurnoniae-infected rat lung tissue. Pharm. Res. (2001) 18(6):780–787.
   PubMedGoogle Scholar
• GOINS BA, PHILLIPS WT: The use of scintigraphic imaging as a tool in the development of liposome formulations. Frog. Lipid Res. (2001) 40(1-2):95–123.
   PubMed Web of Science ®Google Scholar
• SCHIFFELERS RM, BAKKER- WOUDENBERG IA, STORM G: Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene) glycol coating. Biochim. Biophys Acta (2000) 1468(1-2):253–261.
   PubMedGoogle Scholar
• SCHIFFELERS RM, BAKKER-WOUDENBERG IA, SNIJDERS SV, STORM G: Localization of sterically stabilized liposomes in Klebsiella pneumoniae-inTected rat lung tissue: influence of liposome characteristics. Biochim. Biophys. Acta (1999) 1421(2):329–339.
   PubMedGoogle Scholar
• BAKKER-WOUDENBERG IA, LOKERSE AF, TEN KATE MT, MOUTON JW, WOODLE MC, STORM G: Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. .1 Infect. Dis. (1993) 168(1):164–171.
   Google Scholar
• BAKKER-WOUDENBERG IA, TEN KATE MT, STEARNE-CULLEN LE, WOODLE MC: Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-inTected lung tissue../. Infect. Dis. (1995) 171(4):938–947.
   Google Scholar
• DI NINNO VL, CHERWANOGRODZKY JW, WONG JP: Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of BALB/c mice against Francisella tularensis. J. Infect. DA (1993) 168(3):793–794.
   PubMedGoogle Scholar
• MAGALLANES M, DIJKSTRA J, FIERER J: Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. Antimicrob. Agents Chemother (1993) 37(11):2293–2297.
   PubMed Web of Science ®Google Scholar
• WEBB MS, BOMAN NL, WISEMAN DJ et al.: Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob. Agents Chemother. (1998) 42(1):45–52.
   PubMed Web of Science ®Google Scholar
• BAKKER-WOUDENBERG IA, TEN KATE MT, GUO L, WORKING P, MOUTON JW: Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob. Agents Chemother. (2002) 46(8):2575–2581.
   PubMedGoogle Scholar
• BAKKER-WOUDENBERG IA, TEN KATE MT, GUO L, WORKING P, MOUTON JW: Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. (2001) 45(5):1487–1492.
   PubMedGoogle Scholar
• ELLBOGEN MH, OLSEN KM, GENTRY-NIELSEN MJ, PREHEIM LC: Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. .1 Antimicrob. Chemother (2003) 51(1):83–91.
   Google Scholar
• FIELDING RM, LEWIS RO, MOON-MCDERMOTT L: Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm. Res. (1998) 15(11):1775–1781.
   PubMed Web of Science ®Google Scholar
• FIELDING RM, MOON- MCDERMOTT L, LEWIS RO, HORNER MJ: Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey. Antimicrob. Agents Chemother (1999) 43(3):503–509.
   PubMed Web of Science ®Google Scholar
• DHILLON J, FIELDING R, ADLER-MOORE J, GOODALL RL, MITCHISON D: The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J. Antimicrob. Chemother. (2001) 48(6):869–876.
   PubMedGoogle Scholar
• DONALD PR, SIRGEL FA, VENTER A et al.: The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. Antimicrob. Chemother. (2001) 48(6):877–880.
   Google Scholar
• KRIEGER J, CHILDS S, KLIMBERG I: UTI treatment using liposomal amikacin (MiKasome). 9th meeting ECCMID, Berlin, Germany (1999) P194.
   Google Scholar
• XIONG YQ, KUPFERWASSER LI, ZACK PM, BAYER AS: Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus microbiological and echocardiographic analyses. Antimicrob. Agents Chemother (1999) 43:1737–1742.
   PubMed Web of Science ®Google Scholar
• XIONG YQ, ADLER-MOORE J, ZACK P: Efficacy of MiKasome® (a liposomal amikacin formulation) versus free amikacin in experimental endocarditis due to Pseudomonas aeruginosa. 97th General meeting ASM, Miami Beach, USA (1997) A30.
   Google Scholar